Fulvestrant Injection, Solution
Product Images NDC 83634-203

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Fulvestrant (NDC 83634-203). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avenacy, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Ful0c 0000 01)

Figure 1 (Ful0c 0000 01)
FDA Label Image

Figure 2 (Ful0c 0000 02)

Figure 2 (Ful0c 0000 02)
FDA Label Image

Figure 3 (Ful0c 0000 03)

Figure 3 (Ful0c 0000 03)
FDA Label Image

Figure 4 (Ful0c 0000 04)

Figure 4 (Ful0c 0000 04)
FDA Label Image

Figure 5 (Ful0c 0000 05)

Figure 5 (Ful0c 0000 05)
FDA Label Image

Structural Formula (Ful0c 0000 06)

Structural Formula (Ful0c 0000 06)
FDA Label Image

Figure 6 (Ful0c 0000 07)

Figure 6 (Ful0c 0000 07)
This is a presentation of Progression-Free Survival (ITT Population) data for Fulvestrant 250mg and 500mg over a period of 45 months. The graph shows the number at risk at various time points for both doses of Fulvestrant. The data allows for an analysis of the effectiveness of each dose in terms of maintaining progression-free survival over time.*
FDA Label Image

Figure 7 (Ful0c 0000 08)

Figure 7 (Ful0c 0000 08)
FDA Label Image

Figure 8 (Ful0c 0000 09)

Figure 8 (Ful0c 0000 09)
FDA Label Image

Figure 9 (Ful0c 0000 10)

Figure 9 (Ful0c 0000 10)
FDA Label Image

Figure 10 (Ful0c 0000 11)

Figure 10 (Ful0c 0000 11)
This is a survival probability chart showing the number of patients at risk over time for different treatment groups. The text provides information on two treatment groups: fulvestrant with palbociclib and fulvestrant with placebo. The number of patients at risk in each group is shown at various time points from 12 to 48 months. Additionally, the abbreviations FUL, PAL, and PCB are defined as fulvestrant, palbociclib, and placebo, respectively.*
FDA Label Image

Figure 11 (Ful0c 0000 12)

Figure 11 (Ful0c 0000 12)
FDA Label Image

Figure 12 (Ful0c 0000 13)

Figure 12 (Ful0c 0000 13)
FDA Label Image

Figure 13 (Ful0c 0000 14)

Figure 13 (Ful0c 0000 14)
FDA Label Image

Figure 14 (Ful0c 0000 15)

Figure 14 (Ful0c 0000 15)
FDA Label Image

Package Label – Principal Display Panel – Syringe Label (Ful0c 0000 16)

Package Label – Principal Display Panel – Syringe Label (Ful0c 0000 16)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.